PR Newswire, Tuesday, September 09, 1997 at 11:01
JERSEY CITY, N.J., Sept. 9 /PRNewswire/ -- M.H. Meyerson & Co., Inc.
(NASDAQ:MHMY) announced, "In our opinion, Colorado MEDtech, Inc.
(Nasdaq: CMED, approximate price $5-7/8) should continue to be purchased at
current levels. We believe the Company has many good opportunities in front
of them. After the recent acquisition, we have raised our long-term price
target to $12-$14." For further information or copy of the recent research
report, please contact Andrew H. Scott, Research Analyst, of M.H. Meyerson &
Co., Inc., 525 Washington Blvd, Jersey City, New Jersey, 07310. Contact
Andrew H. Scott, at 201-459-9440 or 800-422-4114; web site:
mhmeyerson.com
M.H. Meyerson & Co., Inc. is a market maker in CMED, and may be long or
short positions in this stock from time to time. Customers of the firm also
hold positions in the stock.
SOURCE M.H. Meyerson & Co., Inc.
-0- 09/09/97
/CONTACT: Andrew H. Scott of M.H. Meyerson & Co., 201-459-9440 or
800-422-4114, or www.mhmeyerson.com / |
